Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present argenx SE (NASDAQ: ARGX).

Full DD Report for ARGX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARGX)

Principia Biopharma Readies $75 Million IPO Plans
Quick Take Principia Biopharma ( PRNB ) intends to raise $75.0 million from the sale of its common stock, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for pemphigus, purpura and other diseases. PRNB is a mid-stage biopharma...
Source: SeekingAlpha
Date: September, 06 2018 10:42
Argenx receives feedback on Phase 3 clinical trial for efgartigimod in generalized myasthenia gravis
Argenx (NASDAQ: ARGX ) has received feedback from the Pharmaceuticals and Medical Devices Agency in Japan on the design of a Phase 3 trial and regulatory pathway towards marketing authorization of efgartigimod (ARGX-113) in patients with generalized myasthenia gravis (gMG). More news on:...
Source: SeekingAlpha
Date: August, 29 2018 07:42
Principia Biopharma Begins U.S. IPO Effort
Quick Take Principia Biopharma ( PRNB ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The clinical-stage biopharmaceutical firm researches and develops pharmaceutical treatments for inflammatory and autoimmune diseases. ...
Source: SeekingAlpha
Date: August, 22 2018 11:49
Argenx up 4% premarket on license of ARGX-115 to AbbVie
Argenx (NASDAQ: ARGX ) is up  4%  premarket on light volume on the heels of its announcement that AbbVie (NYSE: ABBV ) has exercised its option for exclusive rights to GARP inhibitor ARGX-115 as allowed under their April 2016 agreement. More news on: Argenx SE, AbbVie Inc., Hea...
Source: SeekingAlpha
Date: August, 22 2018 07:52
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the exercise by AbbVie of ...
Source: GlobeNewswire
Date: August, 22 2018 02:00
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the Company wil...
Source: GlobeNewswire
Date: August, 09 2018 16:06
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2018 Results - Earnings Call Transcript
argenx SE (ARGX) Q2 2018 Results Earnings Conference Call August 2, 2018, 09:00 AM ET Executives Tim Van Hauwermeiren - CEO Eric Castaldi - CFO Analysts Yatin Suneja - SunTrust Jason Butler - JMP Securities Boris Peaker - Cowen Ted Tenthoff - Piper Jaffray Chris Parri...
Source: SeekingAlpha
Date: August, 05 2018 15:05
Recognize These Week 29 Winners? Top 10 Stocks Across Multiple Financial Algorithms
Week 29 Summary Results “It is not the amount of knowledge that makes a brain. It is not even the distribution of knowledge. It is the interconnectedness.” ― James Gleick, The Information: A History, a Theory, a Flood * Table excludes weekly momentum portfolios m...
Source: SeekingAlpha
Date: July, 22 2018 05:59
Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul...
Source: SeekingAlpha
Date: July, 09 2018 08:00
InflaRx: Buy The Dip
Shares of German biotech InflaRx ( IFRX ) have fallen by 10% since my initial reader inquiry article concluded that staying on the sidelines for a better entry point (due to lack of near term catalysts) was the right decision at that point in time. However, I emphatically stated that I ver...
Source: SeekingAlpha
Date: June, 29 2018 08:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0889.5589.7490.9089.0093,691
2018-05-1794.2594.4995.7493.9376,679

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1019,95232,89560.6536Short
2018-12-0719,16842,55245.0461Short
2018-12-0623,626235,46610.0337Cover
2018-12-0462,179129,55347.9950Short
2018-12-0377,740363,78721.3696Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARGX.


About argenx SE (NASDAQ: ARGX)

Logo for argenx SE (NASDAQ: ARGX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ARGX)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 12 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 26 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 22 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 01 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: December, 14 2017

       

       


      Daily Technical Chart for (NASDAQ: ARGX)

      Daily Technical Chart for (NASDAQ: ARGX)


      Stay tuned for daily updates and more on (NASDAQ: ARGX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ARGX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ARGX and does not buy, sell, or trade any shares of ARGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/